Table 1.
Published primary studies on the use of remdesivir against coronaviruses: case series and cohort series.
| Author name | study settings | Type of study | Infection classes | Study design | Concluding remarks | References |
|---|---|---|---|---|---|---|
| Brown et al. | United States | Cohort series | human endemic and zoonotic deltacoronaviruses | understand the spectrum of RDV efficacy among human and zoonotic Coronavirus | -RDV inhibits endemic human coronavirus 229E and OC43 and a member of the deltacoronavirus genus, PDCoV, which have the most divergent RdRp of known coronaviruses compared to SARS and MERS CoVs. -RDV as a potential antiviral for current endemic and epidemic coronavirus as well as future emerging coronavirus | [22] |
| Sheahan et al. | United States | Cohort series | epidemic and zoonotic coronaviruses | Evaluate the antiviral potency and extent of activity of GS-5734 (RDV) against a diverse panel of human and zoonotic coronaviruses. | -RDV may prove effective against endemic MERS coronavirus in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future | [11] |
| Grein et al. | United States | – | MERS-CoV | compare the prophylactic and therapeutic efficacy of RDV with the combination of LPV/RTV and IFNb | -RDV may improve disease outcomes in coronavirus -infected patients, serve to protect health care workers in areas with endemic MERS-CoV and prove valuable in preventing future epidemics in the event of novel coronavirus emergence in the future. | [25] |
| Gordon et al. | Canada | Cohort series | COVID-19 | compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support | - RDV may have clinical benefit in patients with severe Covid-19. - The type of supportive care (e.g., concomitant medications or variations in ventilatory practices) and differences in institutional treatment protocols and hospitalization thresholds may impact on outcomes.- | [29] |
| Agostini et al. | United states | Cohort series | human CoV | Asses the efficacy of the nucleotide prodrug remdesivir (GS-5734) to include a group β-2a CoV | - RDV is highly active against coronaviruses and that there is a high genetic barrier to achieve resistance. - potential novel determinants of polymerase function and nucleotide selectivity or fidelity that will guide future structure-function and biochemical studies of the polymerase and RDV mechanism are identified. - RDV demonstrate its potential utility in the broad-spectrum treatment of coronavirus infections. | [21] |
| Zhong et al. | Beijing, China | – | 2019-nCoVs | Measurement of the effects of these compounds on the cytotoxicity, virus yield and infection rates of 2019-nCoVs. | -RDV is highly effective in the control of 2019-nCoV infection in vitro | [15] |
Abbreviations: PDCoV, Porcine deltacoronavirus; LPV, Lopinavir; RTV, Ritonavir; IFNb, Inc. Recombinant human interferon beta.